Mexico Addiction Therapeutics Market Analysis

Mexico Addiction Therapeutics Market Executive Summary

Mexico addiction therapeutics market was valued at $152 Mn in 2022 and is estimated to reach $263 Mn in 2030, exhibiting a CAGR of 7.15% during the forecast period.

A variety of techniques, interventions, and approaches are used in addiction therapy to treat and prevent addiction. Its main goal is to reduce or eliminate substance abuse, especially drug and alcohol abuse, in order to support those who are struggling with both co-occurring illnesses and dependency. Effective addiction treatment usually takes a customized, all-encompassing strategy, considering each patient's unique situation, past drug use, co-occurring conditions, and social networks. Methadone and buprenorphine are two commonly used drugs prescribed as part of continuing treatment for opioid use disorder addiction. Acamprosate, disulfiram, and naltrexone are a few more drugs that are approved for the treatment of substance use disorders; however, they might not be started until after detox is over.

In Mexico, the drug landscape has changed significantly, with domestic consumption going from historically low levels to a significant increase in recent years. The country is known for its role as a transit point for illegal drug shipments to the north, leading to increased domestic drug consumption. The prevalence of synthetic drugs has increased significantly, as evidenced by the significant increase in addicts seeking treatment for methamphetamine addiction, increasing from 15% to 36% in government treatment centres. Mexico has evolved from a mere transit country for pharmaceuticals from the Andes region to an expanding consumer market. The United Nations World Drug Report highlighted that from 2013 to 2020, Mexico experienced a staggering 218% increase in people seeking treatment for synthetic drug abuse. With an overall 22% increase in drug use, with the COVID-19 pandemic exacerbating this increase. Opioid and marijuana use among young people increased by 18% to 21% during the pandemic in Mexico.

Working with experts from around the world, the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz in Mexico is evaluating the possibility of psilocybin therapy as a treatment for alcoholism in Mexican patients. In order to address regional gaps in healthcare access, the Secretaría de Salud has simultaneously established strategic efforts aimed at increasing awareness and improving access to medication-assisted therapy (MAT) in rural areas.

Market Dynamics

Market Growth Drivers

Increasing Substance Addiction Rates: The usage of synthetic drugs like methamphetamine has led to an increase in substance addiction in Mexico. Drug addiction therapies and treatment services are in greater demand as a result of the rise in drug use.

Awareness and Education Initiatives: The market for addiction therapies is growing as a result of ongoing campaigns, educational programs, and initiatives by governmental and non-governmental organizations that work to lessen stigma, support early intervention, and encourage help-seeking behaviours.

Shifting Drug Consumption Patterns: The nation has changed from being largely a transit country for illegal drugs to a consumer market. Effective addiction therapeutics are more important than ever to treat substance abuse in Mexico.

Market Restraints

Resource Constraints: Insufficient access to specialized facilities and qualified medical personnel makes it difficult to offer complete and efficient addiction therapeutics in response to demand. This limitation of skilled workers and specialized facilities constrains the growth of addiction therapeutics market.

Stigma and Awareness: Addiction therapy may not be adopted if stigma associated with mental health and addiction prevents people from getting treatment or assistance; this stigma associated with substance abuse restricts the market's potential for expansion.

High Cost of Treatment: Due to its high costs, a significant portion of the population, particularly those from lower socioeconomic classes, may find private addiction treatment to be expensive. It's probable that a large number of individuals from lower socioeconomic backgrounds will find it challenging to get access to reputable private addiction treatment services.

Healthcare Policies and Regulatory Landscape

The Federal Commission for Protection against Health Risks, often known as COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), is the regulatory body in Mexico in charge of regulating pharmaceuticals, including treatments for addiction. Pharmaceutical product regulation, authorization, supervision, and control, including importation, distribution, and marketing, are within the purview of COFEPRIS, which is housed under the Secretaría de Salud, the Ministry of Health. Before medications, including addiction therapies, are put on the Mexican market, COFEPRIS performs a critical role in verifying that they meet safety, efficacy, and quality criteria. To ensure the appropriate use of pharmaceutical products and protect public health, it conducts inspections, reviews and approves drug registration applications, and keeps an eye on manufacturing procedures. Before these products can be lawfully marketed and made available for medical use, entities wishing to manufacture, import, distribute, or commercialize addiction therapeutic drugs in Mexico must adhere to COFEPRIS regulations, submit pertinent documentation, and obtain approvals from the authority.

Competitive Landscape

Key Players

• Pfizer
• Johnson & Johnson
• Novartis
• Bristol Myers Squibb
• Merck
• GlaxoSmithKline
• Sanofi
• AbbVie
• Eli Lilly and Company
• Boehringer Ingelheim